MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company ...
PDS Biotechnology (PDSB) reaffirmed the Company’s guidance of initiating its VERSATILE-003 Phase 3 clinical trial of Versamune HPV plus ...
News Medical on MSN2d
Insilico Medicine announces developmental candidate benchmarks and timelines for novel therapeutics discovered using generative AIInsilico Medicine ( “Insilico”) , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today ...
JMP Securities reaffirmed their market outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) in a report released on Tuesday,Benzinga reports. JMP Securities currently has ...
Investment analysts at HC Wainwright dropped their Q2 2025 earnings estimates for Enanta Pharmaceuticals in a report released on Tuesday, February 11th. HC Wainwright analyst E. Arce now expects that ...
Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics and headquartered in Switzerland, ...
Yelena Korochkina, winner of the 2024 Presidential Prize in Science and Innovation for Young Scientists The prize was awarded for developing innovative methods for the effective implementation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback